SUBSCRIBE: Print / eNewsletter
FDA Approves Nivolumab for Treating Liver Cancer
The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.
Lenvatinib for Unresectable Liver Cancer Noninferior to Sorafenib
Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma.
Adjuvant Oral Chemo in Biliary Tract Cancer Extended Survival
The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study.
FDA Approves Regorafenib for Liver Cancer
The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.
Nivolumab Yields 12-Month Survival of Nearly 60% in Advanced HCC
Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma.
Young Obese Men at Risk for Liver Cancer
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.
SBRT Equivalent to TACE as Bridge to Transplant for Patients With HCC
Use of stereotactic body radiation therapy (SBRT) was equally effective as transarterial chemoembolization (TACE) as a method of bridge to transplant among patients with hepatocellular carcinoma.
Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
Disparities Still Exist for HCC Incidence, Survival in United States
A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.